SEC Company Response from Axovant Gene Therapies Ltd. (CIK 0001636050) — Nov 10, 2020
Axovant Gene Therapies Ltd. (CIK 0001636050)
Date: Nov. 10, 2020 · CIK: 0001636050 · Accession: 0001636050-20-000073
AI Filing Summary & Sentiment
File numbers found in text: 333-249279
Letter
Re: Axovant Gene Therapies Ltd.
Document
November 10, 2020
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, DC 20549
Attention: Tim Buchmiller
Registration Statement on Form S-4
File No. 333-249279
Acceleration Request
Request Date: Thursday, November 12, 2020
Request Time: 5:00 P.M. Eastern Standard Time
Ladies and Gentleman:
Axovant Gene Therapies Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it may become effective at 5:00 p.m. Eastern Time on November 12, 2020, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.
Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Company at (650) 843-5059, or in his absence, Milson Yu at (650) 843-5296.
[Signature Page Follows]
Very truly yours,
Axovant Gene Therapies Ltd.
Show Raw Text
CORRESP 1 filename1.htm Document November 10, 2020 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: Axovant Gene Therapies Ltd. Registration Statement on Form S-4 File No. 333-249279 Acceleration Request Request Date: Thursday, November 12, 2020 Request Time: 5:00 P.M. Eastern Standard Time Ladies and Gentleman: Axovant Gene Therapies Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it may become effective at 5:00 p.m. Eastern Time on November 12, 2020, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time. Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Company at (650) 843-5059, or in his absence, Milson Yu at (650) 843-5296. [Signature Page Follows] Very truly yours, Axovant Gene Therapies Ltd. By: /s/ David Nassif David Nassif Principal Financial Officer cc: Pavan Cheruvu, Axovant Gene Therapies Ltd. John McKenna, Cooley LLP Milson Yu, Cooley LLP